GSK plc (NYSE:GSK) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors cut its position in GSK plc (NYSE:GSK - Free Report) by 93.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,522 shares of the pharmaceutical company's stock after selling 1,138,322 shares during the quarter. Captrust Financial Advisors' holdings in GSK were worth $2,723,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Indiana Trust & Investment Management Co lifted its holdings in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after buying an additional 500 shares in the last quarter. Crews Bank & Trust acquired a new stake in shares of GSK in the fourth quarter valued at $26,000. ST Germain D J Co. Inc. boosted its holdings in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the period. Sierra Ocean LLC purchased a new position in GSK in the fourth quarter valued at $32,000. Finally, Parkside Financial Bank & Trust increased its holdings in GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 818 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GSK. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Stock Up 3.6%

NYSE:GSK traded up $1.32 during midday trading on Thursday, hitting $37.54. 7,527,723 shares of the company were exchanged, compared to its average volume of 4,825,151. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The company has a market capitalization of $77.45 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a fifty day simple moving average of $37.48 and a 200 day simple moving average of $35.98.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. As a group, equities analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio is presently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.